Get the Stockscreener App
0.8985
2.43%
0.0213
After Hours:
.81
-0.0885
-9.85%
180 Life Sciences Corp stock is traded at $0.8985, with a volume of 20,642.
It is up +2.43% in the last 24 hours and down -16.03% over the past month.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
See More
Previous Close:
$0.8772
Open:
$0.862
24h Volume:
20,642
Relative Volume:
0.21
Market Cap:
$3.73M
Revenue:
-
Net Income/Loss:
$-3.12M
P/E Ratio:
-0.1866
EPS:
-4.8149
Net Cash Flow:
$-2.69M
1W Performance:
+30.03%
1M Performance:
-16.03%
6M Performance:
-79.25%
1Y Performance:
-52.96%
1-Day Range:
$0.813
$0.90
1-Week Range:
$0.72
$0.9365
52-Week Range:
$0.6578
$17.75
180 Life Sciences Corp Stock (ATNF) Company Profile
Name
180 Life Sciences Corp
Sector
Industry
Phone
650-507-0669
Address
3000 EL CAMINO REAL, PALO ALTO
Compare ATNF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNF
180 Life Sciences Corp
|
0.8985 | 3.73M | 0 | -3.12M | -2.69M | -4.8149 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
180 Life Sciences Corp Stock (ATNF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-21 | Initiated | Maxim Group | Buy |
180 Life Sciences Corp Stock (ATNF) Latest News
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Arrowstreet Capital Limited Partnership Has $312,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART) - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Elray Resources Announces Strategic Sale of Crypto iGaming Technology - ADVFN
Pre-market Movers: VERO, WORX, QLGN, VINC... - RTTNews
Weiss Ratings Reiterates Sell (E+) Rating for 180 Life Sciences (NASDAQ:ATNF) - Defense World
180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reaffirmed at Weiss Ratings - The AM Reporter
ATNF stock touches 52-week low at $0.74 amid market shifts - Investing.com India
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors - ACCESS Newswire
180 Life Sciences Corp. SEC 10-K Report - TradingView
ATNF stock touches 52-week low at $0.98 amid market shifts - Investing.com
Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Increases By 67.2% - Defense World
180 Life Sciences (NASDAQ:ATNF) versus Immunic (NASDAQ:IMUX) Head to Head Comparison - Defense World
Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR
180 Life Sciences (NASDAQ:ATNF) Given Sell (E+) Rating at Weiss Ratings - Defense World
180 Degree Capital (NASDAQ:TURN) Given Sell (D-) Rating at Weiss Ratings - Defense World
Synergy CHC (SNYR) Projected to Post Earnings on Monday - Defense World
Zydus Lifesciences shares rally 3% after FDA approval for prostate cancer drug - The Economic Times
Janone Inc. (NASDAQ:ALTS) Short Interest Up 40.9% in February - Defense World
180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 29.3% in February - Defense World
180 Life Sciences Corp. (NASDAQ:ATNF) Sees Large Growth in Short Interest - Armenian Reporter
ATNF stock touches 52-week low at $1.1 amid market fluctuations - Investing.com
Contract wins and repeat business fuel progress at life sciences company - The Business Desk
180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Down 50.4% in February - Defense World
Short Interest in ArrowMark Financial Corp. (NASDAQ:BANX) Expands By 62.6% - Defense World
American Rebel Holdings, Inc. (NASDAQ:AREB) Sees Large Growth in Short Interest - Defense World
ATNF stock touches 52-week low at $1.14 amid market shifts - Investing.com India
Global Dupuytrens Disease Market Deep Research 2025-2032 | Endo - openPR
180 Life Sciences Appoints New Chief Accounting Officer - TipRanks
180 Life Sciences (NASDAQ:ATNF) Receives Sell (E+) Rating from Weiss Ratings - Armenian Reporter
180 Life Sciences (NASDAQ:ATNF) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
TURN180 Degree Capital Corp Latest Stock News & Market Updates - StockTitan
180 Life Sciences Corp. modifies former CEO's exit terms - MSN
180 Life Sciences Corp. modifies former CEO’s exit terms By Investing.com - Investing.com India
180 Life Sciences Corp. modifies former CEO's exit terms By Investing.com - Investing.com Canada
180 Life Sciences Appoints New CEO Amid Leadership Changes - TipRanks
Anavex Q1 2025 Earnings: Strategic Growth Updates Coming February 12 - StockTitan
180 Life Sciences (NASDAQ:ATNF) Earns “Sell (E+)” Rating from Weiss Ratings - Defense World
Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y - Yahoo Finance
Sai Life Sciences Shares Continue To Decline, Slumps Over 11% In A Week Despite Expansion Plans - Free Press Journal
180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration - ACCESS Newswire
180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector - ACCESS Newswire
180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules - ACCESS Newswire
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why - Nasdaq
180 Life Sciences Corp Stock (ATNF) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):